Advertisement

Picture EBD Group BioPharm America 2018 Boston September 600x60px
Document › Details

Evotec AG. (10/4/16). "Press Release: Evotec and Carrick Therapeutics Build Strategic Alliance". Hamburg.

Organisations Organisation Evotec AG (FSE: EVT, TecDAX)
  Group Evotec (Group)
  Organisation 2 Carrick Therapeutics Ltd.
  Group Carrick Therapeutics (Group)
Products Product drug discovery
  Product 2 cancer drug
Index terms Index term Carrick Therapeutics–Evotec: drug discovery services, 201610– collab strategic alliance discovery + preclinical services for novel oncology targets
  Index term 2 Carrick Therapeutics–Evotec: investment, 201610 1st financing round totalling $95m incl up to $6m from co-investor Evotec AG
Persons Person Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey)
  Person 2 Sullivan, Elaine (Carrick Therapeutics 201501– CEO before Eli Lilly + Evotec 2015H1– Supervisory Board Member)
     


- Evotec contributes $ 6 m to Carrick's $ 95 m funding round through a top-class global investor consortium

- Carrick Therapeutics ("Carrick") and Evotec build discovery alliance for novel oncology targets


Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that in line with its strategy to participate in promising corporate formations it will deepen its already existing relationship with Carrick. Evotec will invest up to $ 6 m towards Carrick's latest funding round. The total $ 95 m round was led by ARCH Venture Partners and Woodford Investment Management with participation from Cambridge Enterprise Seed Funds, Cambridge Innovation Capital, Google Ventures (GV), Lightstone Ventures, and Evotec AG.

Carrick, headquartered in Dublin with R&D located in Oxford and Dublin has a clear vision for cancer patients: Its mission is to target the molecular pathways that drive the most aggressive and resistant forms of cancer in order to have a major impact on the lives of patients. Instead of banking on a single compound or biological mechanism, Carrick is building an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient's tumour. To support this mission Evotec will provide its full range of discovery and oncology services, through its discovery and pre-clinical platform. Carrick will progress multiple programmes through hit-to-lead and lead optimisation with the goal of delivering multiple development candidates.

Dr Werner Lanthaler, Chief Executive Officer of Evotec commented: "We are very excited to be part of creating and co-owning a next generation leading oncology company. Putting all Evotec's tools that support innovation and capital efficiency at work will allow Carrick to very rapidly progress a first-in-class oncology pipeline."

Chief Executive of Carrick Therapeutics, Dr Elaine Sullivan, said: "This is a unique new venture in cancer treatment, backed by some of the highest quality investors in the field. There is a significant unmet need in cancer treatment, and targeting aggressive and resistant disease is an area where we can make a real difference to patients' lives. Working with Evotec has allowed us to build a pipeline with optimal speed and highest quality."

No further financial details are disclosed.

Evotec's financial guidance for 2016, also with regard to liquidity, remains unchanged, despite the recent investment in Topas Therapeutics and now Carrick Therapeutics.


ABOUT CARRICK THERAPEUTICS

Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient's tumour. The name Carrick means 'rock' in Irish to emphasise the strong foundation of like-minded scientists, collaborators and investors, and the vision to build a durable world-class company. Carrick has an ambitious patient focussed vision to serve cancer patients around the world by the introduction of ground breaking cancer therapies that will transform the way cancer is treated.


ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer's disease, with Sanofi in the field of diabetes and with Pfizer in the field of tissue fibrosis. For additional information please go to www.evotec.com.


FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com

   
Record changed: 2016-11-02

Advertisement

Picture EBD Group Biotech Showcase 2019 San Francisco BTS January 600x60px

More documents for Evotec (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px




» top